Selected Lactobacillus Strains Inhibit Inflammation in LPS-induced RAW264.7 Macrophages by Suppressing the TLR4-Mediated NF-κB and MAPKs Activation

Pathogenic bacteria, oxidative stress, immunity disorder, and inflammation are involved in inflammatory bowel disease (IBD) development. Lactobacillus acidophilus KLDS 1.0901, Lactobacillus helveticus KLDS 1.8701, and Lactobacillus plantarum KLDS 1.0318 isolated from Chinese fermented dairy food with various functional characteristics, such as antibacterial, antioxidant, and immunomodulatory activity. Therefore, we selected three strains as a potential application for preventing IBD. However, the anti-inflammatory properties of the tested strains are unknown. The current study evaluated the anti-inflammatory potential of the tested strains using the LPS-induced RAW264.7 cells model. The results showed that all tested strains could inhibit iNOS and COX-2 expression, reducing NO and PGE2 production. And all tested strains markedly reduced the production and mRNA expression of proinflammatory cytokines (TNF-α, IL-1β, and IL-6). Moreover, these results may be associated with inhibiting the translocation of NF-κB into nuclear and MAPKs activation. The study can provide evidence for further in vivo studies of Lactobacillus strains to prevent IBD.